Immune-mediated cerebellar ataxias : clinical diagnosis and treatment based on immunological and physiological mechanisms by Mitoma, H. et al.
This is a repository copy of Immune-mediated cerebellar ataxias : clinical diagnosis and 
treatment based on immunological and physiological mechanisms.




Mitoma, H., Manto, M. and Hadjivassiliou, M. orcid.org/0000-0003-2542-8954 (2021) 
Immune-mediated cerebellar ataxias : clinical diagnosis and treatment based on 
immunological and physiological mechanisms. Journal of Movement Disorders, 14 (1). pp. 





This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) 
licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new 
works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative 
works on the same terms. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
10  Copyright © 2021 The Korean Movement Disorder Society
Immune-Mediated Cerebellar Ataxias:  
Clinical Diagnosis and Treatment Based on  
Immunological and Physiological Mechanisms
Hiroshi Mitoma,1 Mario Manto,2,3 Marios Hadjivassiliou4
1Department of Medical Education, Tokyo Medical University, Tokyo, Japan 
2Service de Neurologie, Médiathèque Jean Jacquy, CHU-Charleroi, Charleroi, Belgium 
3Service des Neurosciences, University of Mons, Mons, Belgium 
4Academic Department of Neurosciences, Royal Hallamshire Hospital, Sheffield, UK
ABSTRACT
Since the first description of immune-mediated cerebellar ataxias (IMCAs) by Charcot in 1868, several milestones have been 
reached in our understanding of this group of neurological disorders. IMCAs have diverse etiologies, such as gluten ataxia, postin-
fectious cerebellitis, paraneoplastic cerebellar degeneration, opsoclonus myoclonus syndrome, anti-GAD ataxia, and primary au-
toimmune cerebellar ataxia. The cerebellum, a vulnerable autoimmune target of the nervous system, has remarkable capacities 
(collectively known as the cerebellar reserve, closely linked to plasticity) to compensate and restore function following various path-
ological insults. Therefore, good prognosis is expected when immune-mediated therapeutic interventions are delivered during 
early stages when the cerebellar reserve can be preserved. However, some types of IMCAs show poor responses to immunother-
apies, even if such therapies are introduced at an early stage. Thus, further research is needed to enhance our understanding of the 
autoimmune mechanisms underlying IMCAs, as such research could potentially lead to the development of more effective im-
munotherapies. We underscore the need to pursue the identification of robust biomarkers.
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BACKGROUND: WHERE DO WE STAND?
History of immune ataxias: milestones
Immune-mediated pathophysiological mechanisms frequent-
ly affect the cerebellum, leading to progressive ataxia character-
ized by dysmetria in both motor and cognitive domains.1,2 The 
first documentation of patients with immune-mediated cerebel-
lar ataxias (IMCAs) originated from Charcot.3 In a well-docu-
mented lecture on multiple sclerosis (MS) delivered in 1868, he 
described the presence of cerebellar ataxia (CA) in patients with 
MS, now known as the Charcot’s triad (intention tremor, scan-
ning speech, and nystagmus). Another historical milestone was 
the first report of paraneoplastic cerebellar degeneration (PCD) 
by Brouwer4 in 1919, in which he described the association of 
CA with ovarian cancer.
In the 1980s, the identification of autoantibodies targeting cer-
ebellar neurons led to a breakthrough in IMCAs. First, the dis-
covery of anti-Yo antibody (Ab), an autoantibody described in 
a patient with ovarian cancer, demonstrated the immune nature 
of the insult resulting in PCD.5 This discovery was followed by 
the identification of specific autoantibodies, including anti-Hu, 
anti-Tr, anti-CV2, anti-Ri, anti-Ma2, and anti-VGCC Abs, often 
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associated with specific types of neoplasms, including breast, 
uterine, ovarian, small cell lung carcinoma, and Hodgkin’s lym-
phoma.6 Second, the association of otherwise idiopathic CAs 
with autoantibodies against the cerebellum was also reported 
in patients without evidence of cancer.7-11 Two main clinical en-
tities have been established since then, based on specific clinical 
features and types of associated autoantibodies: gluten ataxia 
(GA) by Hadjivassiliou et al.12 and anti-glutamic acid decarbox-
ylase 65 Abs (GAD 65 Abs)-associated cerebellar ataxia (anti-
GAD ataxia) by Honnorat et al.13 
Finally, in 2008, Hadjivassiliou et al.14 proposed a new clinical 
entity: primary autoimmune cerebellar ataxia (PACA). This en-
tity encompasses all ataxic patients who exhibit features of IM-
CAs but with a serological profile that does not match any of the 
known main etiologies. Diagnostic criteria have been proposed 
recently.15 Thus, it has become easier to apply this diagnosis for 
such atypical patients to consider the use of immunotherapy.
Classification
IMCAs gather diverse etiologies, and the pathophysiology is 
not restricted to the cerebellum, also targeting cerebellar-related 
structures/connections in the central nervous system (CNS). The 
diversity renders the classification of IMCAs challenging. We pre-
viously proposed a classification based on 2 criteria: 1) whether 
the cerebellum is the main target of autoimmunity, and 2) whether 
autoimmunity is generated by a known trigger or not (Table 1).8-11 
In MS, for example, the cerebellum is one of many targets with-
in the CNS. Pure CA types, in which the cerebellum or its relat-
ed structures are the sole target of autoimmunity, include GA, 
postinfectious cerebellitis (PIC), PCD, opsoclonus myoclonus 
syndrome (OMS), anti-GAD ataxia, and PACA. Thus, the term 
IMCAs is reserved for mainly pure or primarily CA, thus exclud-
ing more widespread autoimmune damage such as that seen in 
the context of MS. Although autoimmune limbic encephalitis 
can sometimes be characterized by CA in addition to cognitive/
behavioral deficits and seizures, these conditions should not be 
categorized as IMCAs.
Pure or primarily CA etiologies are divided into two groups: 
1) etiologies in which autoimmunity is triggered by other con-
ditions, such as infection (e.g., PIC), neoplasm (e.g., PCDs), and 
gluten sensitivity (GA), and 2) etiologies in which autoimmunity 
is not triggered by any other condition (e.g., anti-GAD ataxia). 
When autoimmunity is triggered by other conditions, removal 
of the trigger should be the first line of therapy. This approach 
is important because categorization based on the autoimmune 
triggering factors can also offer therapeutic strategies.9-11
In the case of PACA, immune-mediated mechanisms are 
strongly suspected, but the serological profile of the patients 
does not match any of the known diseases in IMCAs.14,15 Thus, 
this group is likely to be heterogeneous and probably includes 
several pathophysiological immune-mediated mechanisms.
Prognosis and pathophysiology
In keeping with the diverse etiologies, IMCAs show charac-
teristically diverse clinical courses (Figure 1).10,11 These diverse 
clinical courses result in two problems when considering ther-
apeutic strategies: the need for early intervention and the un-
clear immune-mediated pathophysiology. 
Cerebellar reserve and early intervention
GA, PIC and the subacute type of anti-GAD ataxia show good 
response to immunotherapy (full or partial recovery and stabi-
lization) (Figure 1). The good prognosis is in part due to the be-
nign transient autoimmune insult, which is also seen in other 
autoimmune diseases. Alternatively, the reversibility can also be 
attributed to specific cerebellar capacity for compensation and 
restoration following the immune insult.16,17 We termed this ca-
pacity the cerebellar reserve.16,17 Various forms of synaptic plas-
ticity and redundant mossy fiber-mediated inputs constitute the 
cerebellar reserve.16,17 Notably, the extent of progression of the 
pathophysiological mechanisms determines the degree of re-
versibility, suggesting the existence of a threshold. Although var-
ious immunotherapies can arrest the progression of the damage 
under this threshold, such intervention may not be accompa-
nied by clinical improvement. Thus, immunotherapies should 
be introduced during the period when the cerebellar reserve is 
above this threshold. Such a threshold can be understood as the 
limit required to obtain a sufficient level of activity in the cere-
bellar circuitry.
Table 1. Classification of IMCAs
Autoimmunity that mainly targets the cerebellum* or its related structures
Cerebellar autoimmunity triggered by another disease or condition
Gluten ataxia (gluten sensitivity)
Postinfectious cerebellitis (infection)
Miller Fisher syndrome (infection)
Opsoclonus myoclonus syndrome† (infection, neoplasm)
Paraneoplastic cerebellar degenerations (neoplasm)
Cerebellar autoimmunity not triggered by another disease or condition
Anti-GAD ataxia‡
Primary autoimmune cerebellar ataxia 
Others
*when cerebellar ataxias are the sole or main symptoms, the cerebel-
lum is presumed to be the main target of autoimmunity. The term IMCAs 
is reserved for mainly pure or primarily cerebellar ataxia, thus excluding 
more widespread autoimmune damage, †opsoclonus myoclonus syn-
drome also includes idiopathic type, ‡anti-GAD ataxia occurs in other 
autoimmune backgrounds, such as neoplasm. IMCAs: immune-mediat-
ed cerebellar ataxias. GAD: glutamic acid decarboxylase. Adapted from 
Mitoma et al. Cerebellum 2016;15:213-232, under the terms of the Cre-
ative Commons CC BY license.8
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Figure 1. Clinical courses of immune-mediated cerebellar ataxias. (A) Six patterns of clinical courses of immune-mediated cerebellar atax-
ias. (B) Schematic diagram of the concept of the cerebellar reserve. PIC: postinfectious cerebellitis, GA: gluten ataxia, OMS: opsoclonus 
myoclonus syndrome, Anti-GAD: anti-glutamic acid decarboxylase ataxia, PCD: paraneoplastic cerebellar degeneration. Adapted from Mi-
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Autoimmune mechanisms and response to treatment
The chronic subtypes of anti-GAD ataxia and PCD show poor 
prognosis (relapse and gradual or rapid progression in Figure 1), 
which reflects poor responsiveness to immunotherapy. The de-
velopment of various autoimmune diseases can be attributed to 
common elementary processes,18 including autoimmunity trig-
gered by deficits in immune tolerance or molecular mimicry, in-
creased permeability of the blood-brain barrier or blood-nerve 
barrier, pathogenic actions of T cells (Th1/17 cells and CD8 T cells) 
or autoantibodies, and exacerbation of local neural inflammation 
(Figure 2). However, unlike the advances in the field of MS, lit-
tle is known about therapeutic autoimmune targets in IMCAs. 
In conclusion, the clinical entity of IMCAs has been established 
during the past three decades. To avoid missing therapeutic op-
portunities at the early stage, we should carefully promote IMCAs 
in the differential diagnosis of all ataxias. We also need more 
research directed toward the identification of new autoimmune 
pathogenesis-based therapies.
GENERAL ISSUES ON DIAGNOSIS AND 
IMMUNOTHERAPIES
Prevalence
Hadjivassiliou et al.19 (2017) investigated the prevalence of 
IMCAs on 1,500 UK patients with progressive ataxia. The au-
thors reported that 30% of the patients had familial/genetic atax-
ia, although some did not show evident family history, and 9% 
of the patients had a cerebellar variant of multiple systemic at-
rophy (prevalence out of total progressive ataxic cases). Apart 
from the above, 25% had definite IMCAs; 20% had GA, and 2% 
had PCD, while 2% had anti-GAD ataxia, 1% had PIC, and <1% 
had OMS. Interestingly, 19% of the patients were classified as 
idiopathic sporadic ataxia. This category probably included a 
large number of patients with PACA.14,15
Among other groups, Gebus et al.20 (2017) reported a smaller 
number of IMCAs patients (2 with PCD and 1 patient with PIC 
among 80 patients). In a systematic study of 684 South Korean 
patients with progressive ataxia, only 21 had IMCAs; 14 patients 
with PCD, 3 patients with PIC, and 4 patients other immune 
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causes.21 The discrepancy might be attributed to a number of 
different factors: The high prevalence of IMCAs in Hadjivassil-
iou’s study19 was due to a large number of patients with GA. GA 
was first characterized and reported by this group and there is 
therefore the potential for referral bias. Another important factor 
is the serological test utilized to make a diagnosis of GA (please 
see section on GA). More recently, the prevalence of GA in Asian 
countries has been found to be higher than was previously esti-
mated.22,23 For example, patients with GA have recently been re-
ported in Japan.23 A survey in China also showed that the preva-
lence rates of positive-anti-transglutaminase 6 (TG6) IgA were 
35% in 100 sporadic CA patients and 9.8% in 51 healthy controls 
(p = 0.001).23 Another factor is the so called “idiopathic” un-
known etiology diagnosis. As discussed above, we have argued 
that this group includes a large number of patients with PACA.8-11 
The newly established diagnostic criteria on PACA15 will be help-
ful in resolving this issue.
Further studies are needed to examine the prevalence of IM-
CAs or GA in progressive CAs. However, early diagnosis and 
intervention is critical during a period when the cerebellar re-
serve is preserved. In this regard, clinicians should always con-
sider the possibility of IMCAs in the differential diagnosis of pa-
tients developing CAs.
Clue to diagnosis
Patients with IMCAs exhibit common clinical manifestations 
in spite of divergent etiology.10,11 The onset of CA is usually acute/
subacute or sometimes chronic/insidious. The presence of other 
autoimmune disorders is common in some patients. The main 
clinical feature is gait ataxia, which influences standing and steady 
walking and is associated with mild limb incoordination and dys-
metria, oculomotor ataxia, and scanning speech. In keeping with 
these symptoms, MRI characteristically shows vermian atrophy, 
which can be a clue for the differential diagnosis from degener-
ative or genetic CAs (Figure 3A). However, it should be acknowl-
edged that MRI can be normal. As the pathology progresses, at-
rophy becomes more evident, preferentially affecting the vermis. 
CSF studies sometimes show the presence of pleocytosis or oli-
goclonal bands. There may be a context of systemic impaired im-
munity (affecting skin, joints or other organs).
Autoantibodies
As discussed earlier in the section on the history of IMCAs, 
identification of autoantibodies is important in the diagnosis 
(Table 2).10,11 Immunohistochemistry may reveal the binding of 
autoantibodies toward cerebellar components; therefore, if avail-
able, it can add further evidence of the diagnosis. Autoantibodies 
in IMCAs can be divided into two categories: 1) autoantibodies 
Figure 2. Possible autoimmune mechanisms underlying MS. Naive CD4+ T cells are first sensitized by myelin antigens in the peripheral 
lymph nodes and differentiate into myelin antigen-specific Th1 or Th17 cells in MS. These peripherally activated Th1 or Th17 cells express 
increased amounts of adhesion molecules that allow them to pass through the BBB. The Th1 and Th17 cells are reactivated by perivascu-
lar macrophages, leading to the invasions into the CNS parenchyma. Reactivated Th1 and Th17 cells secrete interferon-γ and IL-17, which 
induces the infiltration of activated microglia and neutrophils, respectively. These effector cells secrete downstream proinflammatory or cy-
totoxic cytokines/chemokines, leading to demyelination or neuronal damages. These autoimmune processes are classified into several 
steps: activation in the periphery, BBB breakdown, reactivation and inflammation. It is uncertain whether similar autoimmune mechanisms 
underlie immune-mediated cerebellar ataxias. MS: multiple sclerosis, BBB: blood-brain barrier, CNS: central nervous system.
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suggestive of specific etiologies, and 2) nonspecific autoantibod-
ies found in other neurological and systemic conditions, includ-
ing CAs, which provide only possible autoimmune pathophys-
iology. The former types of autoantibodies include antigliadin 
and TG6 Abs in GA, and anti-Yo, Hu, CV2, Ri, and Ma2 Abs for 
PCD.5,6,8,10,11,24 The nonspecific autoantibodies are also subdivid-
ed into two subcategories: autoantibodies that are assumed to 
have pathogenic roles and the nonpathogenic autoantibodies 
(i.e., a diagnostic marker).
The majority of the pathogenic autoantibodies include auto-
antibodies toward ion channels or ion channel-related proteins 
(Ca++ or K+ channel), glutamate receptors, or GABA synthesis en-
zyme (GAD), some of which have been confirmed as pathogenic 
in both in vitro and in vivo preparations.24-34 Impairments of neu-
ral excitability and synaptic transmissions can occur throughout 
the nervous system, such as limbic encephalitis.24-34 We previ-
ously proposed a nomenclature based on the pathogenic role of 
the autoantibody, i.e., the pathogenic Ab to be coined to the name 
of the clinical entity (e.g., anti-GAD ataxia).10,11
Additionally, some autoantibodies are reported to be associ-
ated with CAs in only a few patients. These autoantibodies are 
classified into a category of not-well-characterized autoantibod-
ies. The significance of these autoantibodies remains to be deter-
mined, but their presence can be a clue to the autoimmune eti-
ology of the ataxia.
Principles of treatment
When autoimmunity is caused by another trigger, priority 
should be given to the treatment of the underlying condition: for 
example, gluten-free diet (GFD) in GA and surgical excision or 
chemotherapy and radiotherapy of the neoplasm in PCD (Fig-
ure 4).7-11 For other IMCAs, immediate immunotherapy is rec-
ommended (Figure 4).7-11 
Depending on the rapidity of progression, induction immu-
notherapy can be used to arrest progression of CA, followed by 
maintenance immunotherapy to prevent relapse.9-11 Various im-
munotherapies have been used, ranging from intravenous im-
munoglobulins (IVIg), glucocorticosteroids, mycophenolate, 
plasmapheresis, and rituximab, either alone or in combination, 
and the selection is often based on the etiology and presenta-
tion.9-11 These therapies should be introduced during the peri-
od when the cerebellar reserve is still preserved.
To establish a therapeutic rationale, the following two issues 
need further consideration. First, to date, there are no large-scale 
randomized studies comparing therapeutic strategies for each 
IMCA.9-11 Second, the effects of each therapeutic intervention 
should be quantified with more sensitive biomarkers if possible 
at an early stage of the disease when MRI shows no atrophy. Re-
cent studies highlighted the potential usefulness of MR spectros-
copy as a sensitive biological marker of the response to treatment 
in CA patients.10,11 The ratio of N-acetylaspartate (NAA)/creatine 
(Cr) area is decreased in patients with CAs (Figure 3B) relative 
to the control and increases in those who respond to immuno-
therapy and exhibit clinical improvement.10,11
PARTICULAR ISSUES IN COMMON 
ETIOLOGIES
This section focuses on main etiologies in IMCAs (Table 3).
Gluten ataxia
GA is defined as sporadic CA associated with gluten sensi-
tivity.12 The autoimmunity is triggered by the sensitivity to glu-
ten found in wheat, rye and barley. Gluten, a family of protein 
containing grains, is composed of gliadin and glutenin.
Diagnosis and treatment
GA affects individuals in their 40–50s and exhibits either 
chronic or insidious onset.7-11 Gluten-sensitive enteropathy (co-
eliac disease) is seen in approximately half of the patients.7-11 The 
human leukocyte antigen (HLA) type DQ2 is detected in 70% 
of the patients, and association with other autoimmune diseas-
es, such as thyroiditis, type 1 diabetes mellitus, and pernicious 
anemia, is common.7-11 Patients present with gait ataxia and vari-
able degree of limb ataxia, scanning speech7-11 and, consistently, 
MRI shows vermian involvement.35 GA can be associated with 
CSF abnormalities, with oligoclonal bands in up to 50% of pa-
tients.7-11 The association of sensorimotor axonal neuropathy and 
focal myoclonus, rarely palatal tremor, is sometimes observed.7-11
Figure 3. Patients with IMCAs characteristically show vermian atro-
phy on MRI (A). In MR spectroscopy (B), patients with IMCAs show 
a decrease in the relative NAA/Cr area mainly in the cerebellar ver-
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Diagnosis is based on the presence of serological evidence of 
gluten sensitivity, which is assessed using autoantibody testing. 
Native anti-gliadin Ab (AGA) remains to be the most reliable 
test for the diagnosis.10,11 However, the cutoff level for the diag-
nosis of GA should be noted.36 In GA patients without enterop-
athy, the main autoimmune response occurs within the CNS, 
not the periphery, resulting in low levels of serum AGA.10 The 
calibration process used in certain commercially available AGA 
kits is based on the use of serum from patients with celiac dis-
ease (CD) and, therefore, the cutoff level is too high for the de-
tection of GA.10 Anti-transglutaminase 2 (TG2) Ab, found in 
patients with CD, is negative in 53% of GA patients free of enter-
Table 2. Classification of autoantibodies in IMCAs
Characterized autoantibodies, suggestive of a specific etiology in IMCAs
Well characterized
Anti-gliadin, TG2, TG6 Gluten ataxia
Anti-Yo PCDs; breast, uterus and ovarian carcinomas
Anti-Hu PCDs; small cell lung carcinoma
Anti-CV2 PCDs; small cell lung carcinoma, thymoma
Anti-Ri PCDs; paraneoplastic OMS; breast carcinoma
Anti-Ma2 PCDs; testis and lung carcinoma
Partially characterized
Anti-Tr PCDs; Hodgkin’s lymphoma
Autoantibodies found in various neurological conditions (e.g., CAs), suggestive of autoimmune pathomechanisms
Autoantibodies assumed to have pathogenic roles in the development of CAs
Anti-VGCC (P/Q type) Ca channel dysfunction: anti-VGCC ataxia, PCDs, Lambert-Eaton syndrome
Anti-DPPX K channel dysfunction: anti-DPPX ataxia, limbic encephalitis
Anti-LGI1 K channel dysfunction and AMPA-R: anti-LGI1 ataxia, limbic encephalitis
Anti-CASPR2 K channel dysfunction: anti-Caspr2 ataxia, limbic encephalitis, Morvan syndrome
Anti-mGluR1 mGluR dysfunction: anti-mGluR ataxia, PCDs
Anti-GAD65 (high titer) Low GABA release: anti-GAD ataxia, PCDs, SPS
Anti-MAG Although pathogenic for neuropathy, mechanism still uncertain: anti-MAG ataxia
Autoantibodies with unreported pathogenic actions
Anti-thyroid PACA, thyroid autoimmune diseases
Anti-SSA (Ro), SSB PACA, Sjögren syndrome 
Autoantibodies reported only in a few CA patients, with less characterized significance in ataxia 
Anti-ZIC4 Paraneoplastic (rare)
Anti-PCA2 Paraneoplastic (rare)
Anti-glycine R Paraneoplastic OMS (rare)
Anti-GluRδ2 PIC, unknown
Anti-PKCγ Reported in a few patients with neoplasm
Anti-Ca/ARHGAP26 Reported in a few patients with neoplasm. Unknown
Anti-SOX1 Reported in a few patients with neoplasm. Unknown
Anti-CARP VIII Reported in a few patients with neoplasm. Unknown





Unknown conditions might be PACA. IMCAs: immune-mediated cerebellar ataxias, PCDs: paraneoplastic cerebellar degenerations, CA: cerebellar 
ataxia, PIC: postinfectious cerebellitis, OMS: opsoclonus myoclonus syndrome, PACA: primary autoimmune cerebellar ataxia, TG: transglutaminase, 
VGCC: voltage gated calcium channel, DPPX: dipeptidyl-peptidase-like protein 6, LGI1: leucine-rich glioma-inactivated 1, CASPR2: contactin-asso-
ciated protein-like 2, mGluR1: metabotropic glutamate receptor, GAD65: glutamic acid decarboxylase 65, MAG: myelin-associated glycoprotein, 
ZIC4: zinc finger protein of the cerebellum 4, PCA2: purkinje cell antibody 2, GluRδ2: glutamate receptor delta2, PKCγ: protein kinase C gamma, Ca/
ARHGAP26: Ca/Rho GTPase-activating protein 26, SOX1: sex determining region Y-related high-mobility group box 1, CARP VIII: carbonic anhy-
drase-related protein VIII, Sj/ITPR-1: Sj/inositol 1,4,5-trisphosphate receptor 1, Nb/AP3B2: Nb/adaptor complex 3 B2. Adapted from Mitoma et al. 
MedLink Neurology 2019 Aug 23 (www.medlink.com), with permission of MedLink.11
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opathy.36 However, anti-TG6 Ab is positive in 72% of GA pa-
tients on the basis of AGA.37 Since TG6 is primarily expressed in 
the CNS, anti-TG6 Ab could be an important and possibly more 
specific biomarker.10,11
GFD is the first line of therapy for GA since it can eliminate 
antigens that can trigger immune-mediated mechanisms, simi-
lar to the strategy used in CD.7-11 One large-scale study based on 
43 patients with GA showed significant improvements in CA and 
a decrease in AGA in patients who adhered to GFD, compared 
with those who did not.38 Other reports described the effective-
ness of IVIg in nonresponders to GFD.39 However, it is now con-
sidered that the lack of response to GFD is due to either poor 
adherence to GFD or hypersensitivity to gluten, where a small 
amount of gluten present in commercially available gluten-free 
food or due to cross-contamination can cause strong autoim-
mune reactions perpetuating the cerebellar damage.9-11 Persis-
tently high levels of AGA are present in the above two groups of 
patients.40,41 On MR spectroscopy, patients on strict GFD show 
an increase in the ratio of NAA/Cr area in the cerebellar vermis, 
whereas no such increase is seen in patients on GFD with persis-
tently positive antibodies and those who do not adhere to GFD.42 
Taken together, in patients with persistently high AGA titers or 
no improvement in MR spectroscopy, further dietetic review by 
an expert dietitian should be considered before switching to im-
munotherapy.10,11 When CAs cannot be controlled with GFD, 
maintenance therapy with IVIg or immunosuppressants (e.g., 
mycophenolate mofetil, cyclosporin, and cyclophosphamide) 
is recommended.9-11
Autoimmune pathophysiological mechanisms
Loss of immune tolerance is considered the main mechanism, 
as in coeliac disease.43 Digested gliadin is deamidated and cross-
linked by TG2, leading to the creation of an immunostimula-
tory epitope for HLA-DQ2 or HLA-DQ8 on antigen-presenting 
cells. These epitopes are presented to CD4+ T cells, from which 
cytokines are released to facilitate the production of antibodies 
against gliadin and TG2 (TG2-gliadin complex) (Figure 5).
The neural damage appears to be due to, at least in part, the 
actions of autoantibodies against tissue transglutaminase, a cal-
cium-dependent enzyme located in intra- and extracellular spac-
es. Both anti-TG2 and anti-TG6 Abs recognize and cross-react 
with neurons. Intraventricular administration of anti-TG2 or 
anti-TG6 Abs elicits ataxia in mice.44 TG2 activity is upregulat-
ed through calcium binding, and anti-TG2 Abs bind preferen-
tially to the calcium-activated enzyme conformation.45,46 Taken 
together, antibody-induced deficits of TG2 in its enzymatically 
active conformation can cause cellular dysfunction. The role of 
TG6 in cerebellar function is also supported by the observation 
that mutations in the TGM6 gene can cause CA (spinocerebel-
lar ataxia type 35).47
Although the mechanisms of cell-mediated brain damage re-
main uncertain, the above immunological studies add support 
to the therapeutic rationale of gluten avoidance in food and re-
ductions of anti-TG2/6 and AGAs.
Myoclonic ataxia with refractory celiac disease
CA associated with cortical myoclonus is a rare subtype of 
gluten sensitivity-related neurological disorder.10,11,48 Although 
the myoclonus is of cortical origin, hyperexcitability of the cere-
bral cortex is elicited by cerebellar dysfunction.10,11,48,49 Charac-
teristically, this subtype shows resistance to GFD. The neurologi-
cal refractoriness is associated with residual enteropathy, which 
is detected by repeat duodenal biopsies.9-11 All such patients re-
quire GFD plus immunosuppression, usually with mycophe-
nolate and in some instances cladribine, in addition to anti-ep-
ileptic drugs for the control of the myoclonus.9-11 The prognosis 
remains poor.10,11
Postinfectious cerebellitis
PIC is defined as cerebellar inflammation induced by im-
mune-mediated mechanisms triggered by viral or bacterial in-
fection.7,8,10,11,50 Some groups have termed this type of autoim-
mune ataxia as para-infectious cerebellitis or acute cerebellar 
ataxia.10,11,50,51 However, when the cerebellar inflammation is 
caused by direct invasion of viral or bacterial microorganisms, it 
is called acute cerebellitis.10,11,52
Diagnosis and treatment
PIC affects mostly young children after an episode of infection, 
usually viral infection, most commonly varicella.7,8,10,50-52 Other 
viruses, such as Epstein-Barr virus, Coxsackie virus, influenza 
A and B virus, parainfluenza virus, rubeola virus (measles), ru-















Figure 4. Schematic algorithm of the treatment plan for immune-
mediated cerebellar ataxias. Adapted from Mitoma et al. MedLink 









































Table 3. Clinical profiles of common etiologies of immune-mediated cerebellar ataxias






Anti-GAD ataxia Primary autoimmune cerebellar ataxia
Prevalence among all progressive  
  cerebellar ataxias18
20% 1% 0.8% 3% 2%
Unknown (among 20% of  
  idiopathic sporadic ataxias)
Autoimmune background
Trigger of autoimmunity Gluten ingestion
Postinfectious,  
   children: varicella.  
Adults: EBV,  
mycoplasma
Paraneoplastic  
   (neuroblastoma)  
postinfectious,  
primary autoimmune
Neoplasm (breast, uterus,  
   ovarian, small cell lung  
carcinoma, Hodgkin’s  
disease and others)
Unknown Unknown
HLA Type DQ2 or DQ8 - - - Type DQ2
Well or partially characterized  
  antibodies
Anti-gliadin (IgG/IgA),  
  anti-TG2, TG6
None
Anti-Ri (for  
  paraneoplastic)
Anti-Yo (53%), anti-Hu  
   (15%), anti-CV2 (4%), 
anti-Ri (2%), anti-MA2 
(2%) anti-Tr (5%)9
Anti-GAD65 (high titer) None
Less well characterized  
  autoantibodies
- Anti-Gluδ2 Anti-glycin R (for  
  paraneoplastic)
Anti-VGCC (2%),  
   anti-SOX1, anti-ZIC4, 
PCA-2, anti-Homer3,  






   (immunohistochemistry)  
anti-GAD65 (low titer),  
anti-Homer3, anti-Gluδ2
Associated autoimmune diseases
Celiac disease (47%),  
   thyroid, type 1 diabetes  
mellitus, pernicious  
anemia
- - -
Type 1 diabetes,  
   thyroid, pernicious 
anemia
Thyroid, Sjögren’s, type 1  
   diabetes, primary biliary  
cirrhosis, pernicious anemia, 
vitiligo
Clinical profile
Time course Insidious and chronic Acute Subacute Subacute
Insidious and chronic  
  or subacute
Insidious and chronic
Age and gender 40–50s, females (55%)
Mainly in children,  
  rarely adults
Mainly in children,  
  rarely adults
50–60s, 60s, females (mostly) 50s
Main manifestations of cerebellar  
  involvement
Gait ataxia Gait ataxia
Opsoclonus,  
   myoclonus in addition  
to gait ataxia
Pancerebellar ataxia Gait ataxia Gait ataxia
Associated neurological  
  symptoms
Cortical myoclonus in  
  some, neuropathy
- - -
Epilepsy,  




Oligoclonal bands in  
  some cases
High WBC count. High  
   IgG levels in 50% of  
patients. Oligoclonal  
bands in some
Sometimes; high WBC  
   count and protein  
level
Frequently; elevation in  
   WBCs and protein,  
oligoclonal bands
Sometimes; CSF  
  oligoclonal bands
Not studied
Cerebellar atrophy on MRI
Present depending on  
   duration of ataxia  
before diagnosis
None None
Not at onset but may  
  develop rapidly
Present depending on  
  duration of ataxia
Present depending on  
  duration of ataxia
EBV: Epstein-Barr virus, HLA: human leukocyte antigen, WBC: white blood cell, TG: transglutaminase, VGCC: voltage gated calcium channel, CASPR2: contactin-associated protein-like 2, mGluR: 
metabotropic glutamate receptor, GAD65: glutamic acid decarboxylase 65, ZIC4: zinc finger protein of the cerebellum 4, PCA2: purkinje cell antibody 2, GluRδ2: glutamate receptor delta2, PKCγ: 
protein kinase C gamma, Ca/ARHGAP26: Ca/Rho GTPase-activating protein 26, SOX1: sex determining region Y-related high-mobility group box 1, CARP VIII: carbonic anhydrase-related protein 
VIII. Adapted from Mitoma et al. MedLink Neurology 2019 Aug 23 (www.medlink.com), with permission of MedLink.11
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bulavirus (mumps), and rubella virus (German measles), and 
bacteria, such as Corynebacterium diphtheriae (diphtheria), Bor-
detella pertussis (whooping cough), Salmonella typhi (typhoid 
fever), Legionella (Legionnaires disease), Leptospira (leptospiro-
sis), and Mycoplasma (mycoplasmosis) can be involved.7,8,10,50,52 
Borrelia (Lyme disease) is also implicated. One large-scale study 
based on 73 patients53 showed that 60% of the patients were be-
tween 2 and 4 years of age, and 25% of these patients had vari-
cella, 52% had other viral infections, and 3% developed PIC af-
ter immunization. The mean latency between infection and the 
onset of CAs was 9.9 ± 7.9 days. However, some patients (19%) 
showed no definite preceding infection.
Patients develop mainly acute-onset afebrile gait ataxia, men-
ingeal signs, high intracranial pressure with or without extracer-
ebellar manifestations, such as temporary clouding of conscious-
ness, seizures, altered mental status (e.g., extreme irritability), 
or extracerebellar focal signs.53 The presence of these clinical fea-
tures is often suggestive of direct infective etiology rather than 
immune-mediated mechanisms (PIC).52 Additionally, mild be-
havioral changes, such as mild irritability, hyperactivity, mood-
iness and whining, are sometimes noted by parents and often 
correlate with the severity of CA.52 These manifestations could 
reflect cerebellar cognitive and emotional disorders. CSF studies 
show pleocytosis in most of the patients (roughly equal numbers 
of granulocytes and lymphocytes in approximately 75% of the 
patients, and sometimes lymphocyte predominance in the re-
maining cases) and high CSF/serum IgG index in half of the chil-
dren. Oligoclonal bands are sometimes present.53 MRI is usually 
negative, with no signs of atrophy or abnormal intensity areas.53 
Nevertheless, adult patients can develop cerebellar atrophy after 
several months. 
Since PIC is self-limiting, close observation of the patient is 
recommended.10,11 One large-scale study reported full recovery 
of CAs in 72% of 60 pediatric patients within two months.53 Only 
when the CAs persist or progress are various combinations of 
immunotherapeutic agents available for use.10,11,50 
Autoimmune pathophysiological mechanisms
Autoimmune mechanisms remain obscure. For example, it is 
not certain whether molecular mimicry, observed in Guillain-
Barré syndrome (GBS, a typical infection-induced neuroim-
mune disease), also operates in PIC. Although the lack of cere-
bellar atrophy and self-limiting clinical course suggests immune-
mediated cerebellar functional disorders, the exact mechanisms 
remain unclear. A recent study54 described the unique actions of 
anti-GluRδ Ab, which is associated with PIC in some patients.26 
In one experimental study, injection of an antibody toward the 
putative ligand-binding site of GluRδ2 resulted in endocytosis 
of AMPA receptors and attenuated synaptic transmission and 
ultimately led to the development of ataxic behavior in mice.54 
Interestingly, the endocytosis of AMPA receptors, which has a 
transient nature, could explain the reversibility in PIC. Thus, fur-
Figure 5. Possible autoimmune mechanisms underlying gluten ataxia. Gluten is a complex molecule contained in several grains. The major 
protein components are glutenin and gliadin. Digested gliadin is deamidated and cross-linked by TG2, leading to the creation of an immu-
nostimulatory epitope for HLA-DQ2 or HLA-DQ8 on antigen-presenting cells. These epitopes are presented to CD4+ T cells, from which cy-
tokines are released to facilitate the production of antibodies against gliadin and TG2. The pro-inflammatory cytokines activate cytotoxic 
CD8+ T cells, which in turn promote epithelium tissue damage. It is uncertain how CNS tolerance is broken down to develop cerebellar de-
generations. TG: transglutaminase, CNS: central nervous system, BBB: blood-brain barrier, HLA: human leukocyte antigen.
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ther studies are needed to understand how autoimmune reac-
tions transiently disturb cerebellar function. 
Opsoclonus myoclonus syndrome
OMS has divergent categories, including paraneoplastic, postin-
fectious, and idiopathic.10,11,55-57 It affects mainly children and is 
especially associated with neuroblastoma.10,11,55-57
Diagnosis and treatment
Opsoclonus is characterized by involuntary repetitive, random 
and rapid eye movements in both horizontal and vertical direc-
tions. Action myoclonus is characterized by irregular jerky move-
ments primarily in upper limbs.10,11 Since OMS is usually asso-
ciated with CA, it is known also as opsoclonus myoclonus ataxia 
syndrome.10,11 In keeping with the diverse etiology, some differ-
ences are observed in the clinical profiles of patients with OMS. 
The presence of subacute vertigo at onset, together with CSF ab-
normalities (high leukocyte count and protein content), is more 
common (half of the patients) in idiopathic OMS than in para-
neoplastic OMS. Encephalopathy is more common in parane-
oplastic OMS, although it is also found in at least a few cases of 
idiopathic OMS.55 Anti-Ri Ab, an onconeural Ab, is positive in 
paraneoplastic patients, mainly those with breast cancer.55 On-
coneural Ab and PET scan should be performed to confirm any 
association with neoplasm.7,10,11 
In cases of paraneoplastic OMS, any associated neoplasm 
should be removed first, if possible, followed by a combination 
of immunotherapies (corticosteroids, IVIg, plasmapheresis, im-
munosuppressants, and rituximab).10,11,55-57 Postinfectious OMS 
and some idiopathic OMS are self-limiting. Thus, if symptoms 
persist, immunotherapy should be introduced.10,11,55-57 Several 
studies showed good prognosis in idiopathic OMS compared 
with paraneoplastic OMS.55-57 For example, when a good response 
to immunotherapy was defined as recovery of the modified 
Rankin Score to ≤ 2,55 a good response was reported in 39% of 
patients with paraneoplastic OMS and in 84% of those with id-
iopathic OMS. Relapse occurred in 24% of patients with para-
neoplastic OMS and in 7% of those with idiopathic OMS.55
Autoimmune pathophysiological mechanisms
Autoimmune pathogenesis is based on the presence of CD19+ 
B cells and gamma-delta T cell subsets in the CSF58 as well as peri-
vascular collection of lymphocytes in autopsy cases.59 It should 
be noted that unlike PCD, neither cell loss nor extensive T cell 
infiltration is characteristically evident in paraneoplastic OMS,60,61 
which suggests immune-mediated functional disorders in the 
cerebellar motor controls.
Characteristically in OMS, the autoimmune-induced dysfunc-
tion appears to occur not only within the cerebellum but also in 
inhibitory controls from the cerebellar cortex on cerebellar nu-
clei neurons. It is assumed that the net inhibitory output from 
Purkinje cells (PCs) in the cerebellar cortex is attenuated in both 
opsoclonus and action myoclonus. In ocular motor controls, this 
elicits hyperactivation of the fastigial nucleus neurons, which in 
turn facilitates the activities of excitatory burst neurons, leading 
to a chaotic cascade of events.62 In the cerebro-cerebellar loop, 
the pathway of the dentato-thalamo-cortical tract is hyperacti-
vated, in which even subthreshold inputs can easily activate the 
motor cortex, generating the action myoclonus in limb move-
ments. Consistently, action myoclonus is of cortical origin,48,49 
and a low correlation between the cerebellum and motor cortex 
is observed in functional MRI.63
In conclusion, there is no explanation on how the autoimmune 
processes, typically triggered by diverse pathologies, such as neo-
plasm and infection, commonly produce a unique functional 
deficit, decrease the inhibitory output from the cerebellar cor-
tex and generate hyperexcitability of their targets.
Paraneoplastic cerebellar degeneration
PCD comprises cerebellar degeneration caused by neoplasm-
triggered autoimmunity.5-8,24,64 The presence of characteristic on-
coneural autoantibodies is not only diagnostic for PCD but also 
provides a clue to the specific type of neoplasm underlying PCD 
(Table 2). Although aggressive chemotherapies and immunother-
apies have been attempted, the prognosis remains poor unless 
the underlying cancer can be completely and rapidly eradicated. 
Diagnosis and treatment
PCD shows acute or subacute onset and is sometimes pre-
ceded by prodromal clinical symptoms such as nausea, vomit-
ing, and dizziness, resembling viral infection-related disease.8,24,64 
Subsequently, patients show gait ataxia, which is followed by 
pancerebellar involvement.8,24,64 CSF studies show changes con-
sistent with inflammation, including moderate lymphocytic 
pleocytosis, high protein concentrations, high IgG index, and 
oligoclonal bands.8,24,64 Identification of the characteristic auto-
antibodies helps in the establishment of diagnosis, although se-
ronegative cases have been described.6 Since subacute CAs are 
listed as classical symptoms defined in the 2004 diagnostic cri-
teria,65 a definite diagnosis is based on 1) confirmation of the 
presence of cancer, which develops within 5 years of the diag-
nosis of CA, or 2) appearance of well-characterized onconeural 
Abs (anti-Yo, anti-Hu, anti-CV2, anti-Ri, anti-MA2).65 CA is the 
first manifestation of neoplasm in up to 70% of the patients with 
PCD,64 highlighting the need for systemic evaluation for malig-
nant tumors following the identification of onconeuronal auto-
antibodies.
Following confirmation of the diagnosis, anti-neoplasm ther-
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apies should be introduced immediately to prevent metastasis 
and remove antigen(s) driving the autoimmunity.8,24,64 The selec-
tion of cancer treatment, such as surgery, radiotherapy and/or 
chemotherapy, is based on the type of the neoplasm.8,24,64 Regard-
less of the selected cancer treatment modality, various types of 
immunotherapies (single or combinations of corticosteroids, 
IVIg, plasmapheresis, immunosuppressants, and rituximab) 
should be administered. 
In spite of these treatment protocols, the prognosis is poor.64,66-68 
The response to immunotherapy is generally unsatisfactory,64,66-68 
although therapeutic benefits have been reported in some case 
reports,10 and better prognosis was noted in patients with anti-Tr 
Ab.69 The study of Peterson et al.70 on 22 patients with anti-Yo Ab 
reported therapeutic improvement in less than 10% of the trials 
(one in four trials of plasmapheresis, one in 17 trials of cortico-
steroids, and none in four trials of cyclophosphamide). Further-
more, Rojas et al.71 also reported no benefits from the combina-
tions of immunotherapies in their study of 23 patients with PCDs. 
There have been three long-term studies on survival time.69,72,73 
Candler et al.72 examined the clinical courses of 63 patients with 
paraneoplastic neurological syndromes, including 13 patients 
with PCDs. Three of the 13 (23%) patients with PCDs died be-
fore the final follow-up, and the mean survival time from onset of 
neurological symptoms was 42 months (95% confidence inter-
val: 32–52). Keime-Guibert et al.73 reported a long-term follow-
up study of 16 patients with PCDs. When the clinical benefits 
were determined as a more than one point change in the Rankin 
Score, none of their patients met this criteria (three patients showed 
stabilization). The median survival time from the first therapy 
was 10.2 months (range 2–38). Fourteen of the 16 (88%) patients 
died during the follow-up. The cause of death was cancer-related 
in 9 patients, neurological-related in 3 patients, and unknown 
in the remaining patients. Shams’ili et al.69 examined the rela-
tionship between effectiveness of treatment and associated an-
tibodies in their study of 50 patients with PCDs. The median sur-
vival times from diagnosis were 113 months in patients positive 
for anti-Tr Ab, > 69 months in those positive for anti-Ri Ab, 13 
months in those positive for anti-Yo Ab, and 7 months in those 
positive for anti-Hu Ab. It should be noted that even patients 
with anti-Tr Ab suffered severe disability or dependence. Taken 
together, the survival time is generally short once the diagnosis 
is established, excluding a few patients with anti-Tr Ab.
The poor prognosis could be attributed to the remnant tumor 
tissue and metastasis, which could cause persistent activation of 
the immune system and strong autoimmune response. Current-
ly, clinical trials aimed at stopping the progressive autoimmune 
insults are being conducted. In one such trial, the combination 
of IVIg or plasmapheresis with cyclophosphamide was reported 
to be effective in a subgroup of patients.64
Autoimmune pathophysiological mechanisms
Pathological studies have identified various inflammatory 
changes in the early stages of PCD, including perivascular cuff-
ing by lymphocytes, infiltration of lymphocytes within the PC 
layer, and microglial activation.74,75 The infiltrates consist of both 
of T and B cells, plasma cells, microglia/macrophage lineages, 
and reactive Bergmann cell gliosis.76 A similar infiltration, albeit 
of lower magnitude, was found in the dentate nucleus and the 
pons.77,78 Disease progression is associated with massive loss of 
PC without inflammation (inflammatory cells or deposits of im-
munoglobulins and complements).76,79,80 Since the loss of PC is 
often very rapid, such a burnout stage can be observed in some 
patients at an earlier stage.76,79
Yo (Cdr2) and Hu onconeural antigens are intracellularly lo-
cated in tumor and neuronal cells.81 This favors molecular mim-
icry mechanisms. First, whether autoantibodies that target in-
tracellular antigens Cdr and Hu proteins play pathogenic roles 
in the development of the inflammatory cerebellar lesions is still 
a matter of debate today. Previous studies showed that anti-Yo Ab 
toward Cdr2 was internalized and induced cell death through 
apoptosis.82,83 In this regard, Cdr2 encodes a leucine zipper mo-
tif and interacts with another leucine zipper motif on c-Myc, the 
nuclear transcription factor, to regulate nuclear levels of c-Myc 
and c-Myc-associated signaling activities. Cdr2-specific anti-Yo 
Ab inhibits the interaction of Cdr2 with c-Myc, possibly allow-
ing excess c-Myc to enter the nucleus and impair cell cycle sig-
naling involved in cell apoptosis. The binding of anti-Yo Ab to 
Cdr2 can also disrupt interaction with the mortality factor-like 
proteins MRGX and/or NFkb, leading to changes in transcrip-
tional activity.83 Another study showed that administration of 
anti-Hu and Yo induced the expression of adhesion molecules 
and more intense cell differentiation rather than cell death.84 Fur-
thermore, another histochemical study showed a lack of both IgG 
deposits and B cell infiltration.85 A study of passive transfer of on-
coneural Abs that targeted intracellular antigens and immuni-
zation using protein or DNA failed to induce ataxic symptoms 
in animals.86-88 Thus, many researchers believe that antibody-me-
diated mechanisms are not the main autoimmune mechanisms 
underlying PCDs associated with anti-Yo and anti-Hu Abs.64,85
Patients with anti-Yo (Cdr2) Ab or anti-Hu Ab show accu-
mulation of Cdr2- or Hu-specific T cells in blood and CSF, re-
spectively.89-91 Notably, the lymphocytes found in tumors, periph-
eral blood, and affected nervous tissue are thought to originate 
from the same clone population.81,92 The infiltrated lymphocytes 
in the cerebellum are mainly CD3+ and CD8+ T cells,78,92 and 
only a few are CD4+ lymphocytes.93 In general, CD4+ and CD8+ 
T cell interaction is necessary to induce inflammation, where 
CD4+ T cells exhibit a Th1 phenotype and secrete IFN-γ and 
TNF-α.94 These studies suggest that PCDs are mediated mainly 
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by a CD8+ T-cell immune response toward an autoantigen 
recognized by onconeural Ab.64,81,95,96 The cytotoxic lympho-
cytes appear to be aggressive toward cells presenting Cdr2 or 
Hu antigens and possibly induce cell death through one or 
more of the following mechanisms; 1) activation of TNF and 
FasL receptors, which triggers the apoptotic cell death cascade, 
and 2) excretion of granules that destroy cells through the ac-
tions of granzyme-B, perforin, and T-cell restricted intracellular 
antigen-1 (Figure 6).81
Despite the above evidence suggesting the involvement of cell-
mediated mechanisms in the development of PCDs, the transfer 
of lymphocytes from patients with anti-Yo Ab did not elicit any 
PC damage.97,98 In addition, although all small cell lung carcino-
ma expresses the Hu antigen, and a clinically useful tumor im-
mune response can be detected in up to 20% of the patients, the 
paraneoplastic neurologic syndrome is extremely rare, suggest-
ing the robust tolerance to neural onconeural antigens in vivo.99 
Based on this notion, Blachère et al.100 argued that CD8+ T cells 
that target intracellular antigens, in conjunction with CD4+ T 
cells, can induce tumor autoimmunity, but not neurologic au-
toimmunity. They proposed that 1) CD8+ T cells can only acti-
vate the peripheral immune response and 2) CD8+ T cells can 
break CNS tolerance to induce PCDs if they interact with both 
CD4+ T cells and autoantibodies.100 This interaction between 
cell- and autoantibody-mediated mechanisms might provide the 
rationale for the design of new therapies that can target T and 
B cells using tacrolimus and rituximab, respectively.100 
The following mechanisms can also underlie the break of CNS 
tolerance:101 1) structural modification of certain intracellular 
proteins, which stimulates the immune system, 2) death of can-
cer cells and release of intracellular antigens with subsequent ex-
posure to the immune system, 3) persistence of the above auto-
immune responses to neoplasm causes secretion of cytokines that 
elicit vascular hyperpermeability and infiltration of immune cells, 
and 4) simultaneous downregulation of regulatory T cells.
Anti-GAD ataxia
GAD is an enzyme that catalyzes the conversion of glutamate 
to GABA.102 GAD has two isoforms: GAD65 and GAD67. The 
autoantibodies against the smaller isozyme are associated with 
CA.102 Serum and CSF titers of anti-GAD65 Ab are higher in 
anti-GAD ataxia, at usually more than 10,000 U/mL (or 10 to 
100-fold higher), compared to those of patients with type 1 di-
abetes mellitus (T1DM).13,102 The triggering factor of this auto-
immunity is not clear at present. Anti-GAD ataxia can be asso-
ciated with other types of IMCAs, such as PCD and GA.8 While 
autoimmunity toward GAD65 affects the entire CNS, the cere-
bellum is one of the most vulnerable areas.102 
Figure 6. Possible autoimmune mechanisms underlying paraneoplastic cerebellar degenerations. Naive CD4+ T cells are first sensitized 
by onconeural antigens (for example, Cdr2 or Hu) in the peripheral lymph nodes, and they differentiate into antigen-specific Th1 or ThFH 
cells. Activated CD8+ T cells are aggressive toward cells presenting these onconeural antigens through FasL receptor-mediated or perforin/
granzyme-mediated apoptosis. It is uncertain how CNS tolerance is broken down to develop cerebellar degenerations.
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Diagnosis and treatment
The condition mostly affects women in their 60s, with subacute 
or chronic/insidious time course.8,102,103 Some patients show evi-
dence of other autoimmune conditions, such as T1DM, autoim-
mune thyroid diseases, and pernicious anemia.8,102,103 Anti-GAD 
ataxia is sometimes associated with extracerebellar symptoms, in-
cluding epilepsy, ophthalmoplegia and Stiff-Person syndrome.8,102,103 
The clinical course can be either subacute or chronic.103 CSF stud-
ies sometimes show oligoclonal bands,8,102,103 whereas MRI shows 
normal or atrophic changes depending on the duration of ill-
ness.8,102,103 The diagnosis is confirmed by the presence of high ti-
ters of intrathecally produced anti-GAD Ab.8,102,103
The serum level of anti-GAD antibodies in the context of the 
diagnosis of anti-GAD ataxia merits further consideration. There 
is currently no consensus on the threshold used for “low titer” 
and “high titer” levels of anti-GAD antibodies. In cases of anti-
GAD Ab more than 2,000 U/mL (high titer), one can safely con-
sider anti-GAD ataxia. However, titers in the range of 100–200 
U/mL in an appropriate clinical/biological/neuroimaging con-
text may be observed in immune ataxias. Some patients with 
CA and anti-GAD Ab less than 100 U/mL have been reported 
to show benefits to immunotherapies.102 Anti-GAD Ab less than 
100 U/mL may raise a suspicion of autoimmune diathesis and 
require therapy. It is also important to keep in mind that various 
laboratories use different techniques for the assays.
The aim of any induction therapy should be to minimize pro-
gression of CA.9-11,102 Thus, various immunotherapies, alone or 
in combination (more common), are used until remission.9-11,102 
Maintenance therapies are usually added to prevent any re-
lapse.9-11,102 Both the induction and maintenance therapies in-
clude corticosteroids, IVIg, immunosuppressants, plasmapher-
esis, and rituximab, either alone or in combination.9-11,102 There 
appear to be no significant differences in the therapeutic bene-
fits among the above immunotherapies.9-11,102 The prognosis is 
better in the subacute type than in the chronic type of anti-GAD 
ataxia.103
Autoimmune pathophysiological mechanisms
The significance of anti-GAD65 has been a matter of debate.102,104 
Some researchers have argued that anti-GAD65 Ab have no patho-
genic roles in the development of CAs based on the following rea-
sons:105,106 1) anti-GAD65 Ab plays a pathogenic role in T1DM 
and various neurological conditions, such as Stiff-Person syn-
drome, 2) GAD65 is intracellularly located together with GABA 
transported with the cytosolic phase of GABA-containing vesicles, 
implying that autoantibodies do not have access to GAD65, and 
3) lack of correlation between anti-GAD65 Ab titers and clini-
cal symptoms.107 However, recent physiological studies have pro-
vided substantial evidence for the pathogenic role of anti-GAD 
Ab.102,104 It should be acknowledged that these studies did not rule 
out the secondary involvement of cell-mediated mechanisms.
Epitope-specific actions
Studies using slice-tissue preparations showed that the addi-
tion of CSF IgGs from patients with anti-GAD ataxia to the me-
dium resulted in presynaptic inhibition of GABAergic synapses 
between basket cells and PCs.108,109 Furthermore, in in vivo prep-
arations, application of CSF IgGs resulted in impairment of cer-
ebellar-mediated modulations, as confirmed by various types of 
tasks.110-112 Importantly, these pathogenic actions of IgGs from 
patients with anti-GAD ataxia were elicited by the binding of 
GA65 with anti-GAD65 Ab itself in an epitope-specific fashion: 
1) these actions were abolished after the absorption of anti-
GAD65 Ab using recombinant GAD65113 and anti-GAD65 Ab 
elicited no actions in slices from GAD65 knockout mice where 
inhibitory transmissions were mediated compensatorily by 
GAD67,112 2) the b78 monoclonal Ab with epitope-specificity 
in CAs has pathogenic actions, whereas another monoclonal Ab 
has no such actions in T1DM,111,112 and 3) differences in neuro-
logical phenotype might also be related to epitope specificity.111,112 
Notably, low titer anti-GAD Ab has no pathogenic actions.102,104
Internalization and dissociation of GAD65 with vesicles
Anti-GAD65 Ab is internalized, presumably during exocyto-
sis or endocytosis.112,114 Since exposure of GAD65 is assumed to 
be during exocytosis, anti-GAD65 could access GAD65,102,104 
although the exact mechanisms are still not clear. Anti-GAD65 
Ab is reported to impair the association of GAD65 with vesicles, 
resulting in deficits in GABA packaging into vesicles and shut-
tling of vesicles to the release sites (Figure 7).112
From functional disorders to cell death
A decrease in GABA release attenuates the spill-over GABA-
induced presynaptic inhibition on glutamate release from neigh-
boring parallel fibers, resulting in a major imbalance between 
GABA and glutamate and excitotoxicity (Figure 8).115 Consistent-
ly, one autopsy study showed the complete loss of PCs.116
Clinical correlation
Previous studies showed that some patients respond well to 
immunotherapies and that the clinical improvement in CA cor-
relates well with the fall in Ab titers,9-11 suggesting that Ab titers 
better reflect functional disorders rather than cell death. The peak 
CA might be influenced by secondary cell-mediated mechanisms.
Taken together, the above experimental studies clearly show 
that anti-GAD65 Ab could serve as a trigger of CA (Figure 7). 
These studies also provide a generalized principle regarding an-
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tibody-induced neurological diseases; autoantibodies are poly-
clonal, and a cocktail of these polyclonal autoantibodies determines 
the clinical profile, depending on the proportions of pathogenic 
epitopes. In addition, pathomechanisms underlying the excito-
toxicity could be generalized in other pathologies, such as isch-
emic diseases and degenerative CAs (Figure 8).
Primary autoimmune cerebellar ataxia
Although the clinical profile spectrum of PACA meets the fea-
tures of IMCAs (e.g., subacute onset, autoimmune disease his-
tory, predominant gait ataxia, association of autoantibodies, and 
good benefits from immunotherapies), a subgroup of patients 
present with features that do not meet the criteria of the above 
common subtypes.8, 10,11,14,15,117,118 Thus, the spectrum of PACA 
serves as an umbrella that covers heterogeneous etiologies.8,10,11, 
14,15,117,118 Consistently, various types of less characterized autoan-
tibodies are associated in some patients (Table 2), and immuno-
histochemical studies show a variety of staining patterns (60% 
of the patients).14 Despite the heterogeneity, patients with PACA 
sometimes show HLA type DQ2, which is observed in certain 
autoimmune diseases (CD, GA, T1DM, Stiff-Person syndrome, 
autoimmune thyroid disease and autoimmune polyendocrine 
syndromes), but not in healthy subjects.14,15 
Many types of immunotherapies have been used in PACA. 
A small number of studies have reported the effectiveness of 
IVIg, prednisolone, plasmapheresis or rituximab in 9/19 pa-
tients at the early stage of PACA.119 Progression to wheel-chair 
dependence was faster in patients with neuronal nuclear and/
or cytoplasmic antibody than those positive for plasma mem-
brane protein antibody,14 suggesting the need for the selection 
of therapeutic strategy based on the underlying autoimmune 
pathoetiology. In this regard, MR spectroscopy of the cerebel-
lum could be an important tool in monitoring the response to 
immunotherapies.15,117,118
OTHER RARE ETIOLOGIES IN IMCAs
This section focus on rare etiologies in IMCAs.117,118
Miller Fisher syndrome
In 1956, Fisher120 proposed a new clinical entity of an acute-
onset triad of ophthalmoplegia, ataxia and areflexia syndrome, 
which is currently termed Miller Fisher syndrome (MFS). MFS 
is assumed to be a representative disease of infection-triggered 
autoimmunity, similar to GBS.10 A large-scale study involving 
50 consecutive patients showed that viral infection (usually re-
spiratory infection) or bacterial infection (usually Campylobacter 
jejuni) preceded the appearance of the triad manifestations, with 
a median interval of 8 days.121 High serum titers of the specific 
marker anti-GQ1b Ab are found in up to 90% of patients with 
MFS, but not in those with other autoimmune neuropathies, 
such as GBS and chronic inflammatory demyelinating polyneu-
ropathy. Anti-GQ1b Ab cross-reacts with epitopes present in the 
liposaccharide of MFS-associated Campylobacter jejuni strains, 
suggesting molecular mimicry.122
MFS shows self-limiting clinical course, thus requiring no im-
munotherapy.10 One large-scale study showed full recovery with-
in 6 months in all patients.121 The speed of recovery and the final 
outcome were the same in patients who received corticosteroids, 
IVIg, or plasmapheresis and those who were treated conserva-
tively.121 The good prognosis suggests that any autoimmune-me-
diated impairment in MFS is reversible. It remains to be deter-
mined whether the autoimmune response functionally attacks 
peripheral or central structures. Based on the findings of GQ1b 
expression in large-diameter dorsal ganglion neurons8 and the 
presence of enhanced lesions in the spinocerebellar tracts at the 
lower medulla on MRI,123 several researchers have argued for 
the presence of peripheral lesions in MFS. Moreover, cerebellar 
involvement has been confirmed more directly in a number of 
recent studies. One study using FDG-PET showed hyperme-
tabolism in the cerebellum and brainstem,124 and another study 
Figure 7. Pathogenic actions by anti-GAD65 Ab. Anti-GAD65 Ab 
can be internalized, presumably during exocytosis or endocytosis. 
Since GAD65 is assumed to be exposed during the exocytosis, an-
ti-GAD65 Ab can access GAD65. Anti-GAD65 Ab disturbs the as-
sociation of GAD65 with vesicles, which results in impairments in 
GABA packaging into vesicles and shuttling of vesicles to release 
sites. The decrease in GABA release impairs cerebellar signal for-
mation, leading to disorganized cerebellar controls. Importantly, 
such pathogenic action by anti-GAD65 Ab is epitope-dependent. 
Ab: antibody, GAD: glutamatic acid decarboxylase. Adapted from 
Hadjivassiliou et al. Neuroimmune Diseases: From Cells to the Liv-
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using MR spectroscopy showed abnormal signals in the cere-
bellum during the course of the illness.125 Furthermore, immu-
nocytochemical studies using sera of MFS patients confirmed 
the presence of autoantibodies to antigens in the molecular 
layer.126,127
Recently established clinical entities 
Dipeptidyl-peptidase-like protein-6 (DPPX), an auxiliary sub-
unit of the Kv4.2 potassium channel,128-130 and contactin-asso-
ciated protein-like 2 (Caspr2), a protein associated with the Kv1 
potassium channel,131,132 can be targets of autoimmunity. Since 
potassium channels are distributed throughout the CNS, CAs 
are one of the diverse features of these etiologies. Patients with 
anti-DPPX Ab show multifocal neurological symptoms such as 
agitation, mild confusion, hyperekplexia, myoclonus, trunk stiff-
ness and CAs, which are attributed to the hyperexcitability in-
duced by potassium channel deficits.128-130 Recently, CAs with 
myoclonus were also reported as the sole manifestation of this 
entity.10 Additionally, encephalitis associated with anti-Caspr2 
Ab is defined as ≥ 3 core manifestations, including encephalic 
signs, CAs, peripheral nerve hyperexcitability, dysautonomia, 
neuropathic pain, insomnia, and weight loss.131 Notably, stereo-
typical episodes of paroxysmal CAs (mimicking episodic atax-
ias) are found in some patients with anti-Caspr2 Ab.132 The gait 
imbalance, limb ataxia, and slurred speech usually last a few min-
utes to a few days and usually improve following immunotherapy. 
Figure 8. Overview of the possible synaptic consequences of decreased GABA release in the cerebellum. (Normal GABA regulation) In 
normal conditions, GABA released from GABAergic neurons binds to GABAA receptors located on PC and induces an IPSC. GABA also 
diffuses out of the synapse and binds to GABAB receptors, reducing the release of the excitatory neurotransmitter glutamate. Glutamate ul-
timately activates NMDA receptors on excitatory neurons and is regulated in part through NO. Glutamate is taken up by astrocytes via the 
EAAT pathway. (Functional impairment) When GAD65 Ab is produced intrathecally (①), GAD65 Ab may bind GAD65 and interfere with 
GABA release (②). Reduced GABA levels increase glutamate levels as a consequence of the lower inhibition of GABAB receptors (③). 
Continuously high glutamate levels can develop divergent effects, as detailed in the following (④). Glutamate activates microglia, which in 
turn releases more glutamate (④-1). Saturation or impairment of EAAT will reduce glutamate re-uptake by astrocytes (④-2). Activation of 
xc(-) increases the extracellular glutamate release (④-3). Finally, the NMDA/NO feedback regulation fails. All these effects result in an in-
crease in glutamate concentrations. (Cerebellar atrophy) The excessive Ca2+ influx stimulates calpain I and nNOS, leading to mitochondria 
dysfunction, ER stress and DNA damage (④-4). In this scheme, Purkinje cells and granule cells are assumed. However, NMDA receptors 
are expressed in granule cells, whereas metabotropic glutamate receptors are expressed in Purkinje cells. Mossy fibers strongly excite 
granule cells via NMDA and AMPA receptors, contributing to cerebellar neuronal hyperactivity. GA: GABAA receptors, GB: GABAB receptors, 
GAD: glutamic acid decarboxylase, A: AMPA receptors, N: NMDA receptors, M: metabotropic glutamate receptors, EAAT: excitatory amino 
acid transporters, Blue dots: GABA, Red dots: glutamate, Glu: glutamate, Gln: glutamine, GS: glutamine synthetase, (-): inhibitory effects.
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These two novel entities suggest that the cerebellum is one of the 
vulnerable areas in patients with potassium channel dysfunction.
Myelin-associated glycoprotein (MAG) plays an important role 
in the maintenance of the myelin sheath, not only in Schwann 
cells but also in the CNS.133 The association of anti-MAG Ab with 
distal demyelinating neuropathy is well established in patients 
with monoclonal gammopathy of unknown significance.134 Re-
cently, CA associated with anti-MAG Ab was described in five 
patients.134 All patients had IgM gammopathy, and four of the five 
showed clinically evident neuropathy. MR spectroscopy showed 
cerebellar involvements, which diminished after improvement 
of CAs with rituximab.134 
In contrast to these autoantibody-related etiologies, chronic 
lymphocytic inflammation with pontine perivascular enhance-
ment responsive to steroids (CLIPPERS) is characterized by 
marked perivascular T cell inflammation.135,136 The lymphocytes, 
mainly CD4-dominant lymphocytes, infiltrate the perivascular 
area and more diffusely in the white matter of the pons and ad-
jacent rhombencephalic structures, such as the cerebellar pedun-
cles, cerebellum, medulla, and the midbrain.135,136 The perivascu-
lar infiltration appears as characteristic gadolinium enhancement 
on MRI, with multiple “punctate” and/or “curvilinear” gadolin-
ium enhancing lesions, resulting in “peppering” of the pons with 
or without peripontine lesions.135,136 The conditions affect main-
ly men in their 50s.135,136 The patients show subacute onset of the 
combination of brainstem symptoms and CAs, which include 
pancerebellar ataxias, dysarthria, dysphagia, dysgeusia, oculo-
motor abnormalities, altered facial sensation, facial nerve palsy, 
vertigo, pyramidal signs and sensory disorders.135,136 CLIPPERS is 
characterized by responsiveness to corticosteroids.135,136 The ini-
tial treatment is intravenous methyl prednisolone followed by 
maintenance immunotherapy using the combination of oral pred-
nisolone and corticosteroid-sparing immunosuppressants.135,136 
Since the clinical course seems to be relapsing–remitting in na-
ture, long-term maintenance therapy is required.136
CONCLUSION
IMCAs include diverse etiologies, suggesting that the cerebel-
lum can be the target of many types of autoimmune responses 
with different pathophysiological mechanisms. The identifica-
tion of new clinical entities (anti-DPPX ataxia, anti-Caspr2 atax-
ia, anti-MAG ataxia, and CLIPPERS) suggests that further novel 
entities are likely to be discovered in the near future. IMCAs of 
certain etiologies respond well to immunotherapy at least in the 
early stage, while the cerebellar reserve is preserved. Thus, clini-
cians should identify therapeutic opportunities early.17 Con-
versely, a subgroup of etiologies shows poor prognosis, thus re-
quiring a future breakthrough in therapeutic strategies.137 Further 
advances in our understanding of these complex immune mech-
anisms are important in dictating future immunotherapies. 
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